Yearly Archives: 2021


Stem Cell Clinic > 2021

Global Adult Stem Cells Market Revenue To Witness Humongous Elevation By 2026 Market Research Store Jumbo News – Jumbo News

By Adult Stem Cells

Global Adult Stem Cells Market Witnesses Significant Growth Amid The Latest COVID-19 Pandemic Crisis

The globalAdult Stem Cells marketstudy maps the growth trajectory of the global Adult Stem Cells market by accurately evaluating all the vital factors that have a positive impact on the market growth. The Adult Stem Cells market report is expected to attain an accelerated growth and attain future prospects through the assessment of various facets of the Adult Stem Cells market. According to the report published by theMarket Research Store, the Adult Stem Cells market is predicted to attain vigorous momentum in its growth during the forecast owing to the increasing consumer base and market profiting growth stimulators.

Get PDF Sample Copy of this Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart)@https://www.marketresearchstore.com/report/global-adult-stem-cells-market-report-2018-industry-317645#RequestSample

This report provides all the information regarding market drivers, challenges, opportunities, future scope, and recent developments of theAdult Stem Cells marketonly after a thorough evaluation. Furthermore, to make the report more understandable to the readers it starts with a complete market overview that makes scrolling through the entire content a seamless experience.

The section focusing on competitive landscape of the report help better understand the shoulder to shoulder competition among the major players in the global Adult Stem Cells market. The company profiles provide intense insight of product portfolio, sales strategies, marketing & advertising skills, and distribution analysis of each market player. Some of the leading players evaluated in the report includeGamida Cell Ltd., Clontech, Globalstem, Celyad, Cellular Dynamics International, Epistem Ltd., Biotime Inc., Intellicell Biosciences Inc., Neuralstem, Juventas Therapeutics Inc., Hybrid Organ Gmbh, Cellerant Therapeutics Inc., Beike Biotechnology Co. Ltd., Caladrius Biosciences Inc., Capricor Inc., Neurogeneration, Cellerix Sa, Brainstorm Cell Therapeutics Inc., Mesoblast Ltd., International Stem Cell Corp., Cytori Therapeutics Inc..

Similarly, an exhaustive geographical analysis of the global Adult Stem Cells market covers market attracted regions including North & South America (United States, Mexico, Canada, Brazil, Argentina, Chile, etc.), Europe (Italy, Germany, Russia, UK, Turkey, France, etc.), The Middle East and Africa (South Africa, Sudan, GCC Countries, Egypt, etc.), Asia-Pacific (China, Malaysia, Japan, Vietnam, Singapore, Korea, India, Indonesia, and Australia). The regional market attractiveness helps better understand the market status, accurate statistics, product demand, and overall market revenue. On the whole, the report will provide valid market data that will offer a cutting edge to the investors wanting to invest in the global Adult Stem Cells market. The market report offers accurate and comprehensive assessment of the micro and macro-economic factors and market valuation details that are forecasted to impact the market growth.

Critical aspects provided in the report:

Supply/demand chain analysis, market size, market volume, market revenue, and product pricing analysis Future scope, recent developments, new product launches, and opportunities Market challenges and risks that hinder market growth Progress in terms of product development and innovation Analysis of key competitive players Market attractiveness in various countries/regions

Adult Stem Cells Market, By Product (2020-2026)

Epithelial stem cells, Hematopoietic stem cells

Adult Stem Cells Market, By Application/End-use (2020-2026)

Neurodegenerative diseases, Heart disease, Bone disease, Others

Do You Have Any Query Or Specific Requirement? Ask to Our Industry Expert:https://www.marketresearchstore.com/report/global-adult-stem-cells-market-report-2018-industry-317645#InquiryForBuying

Key Reasons for Purchasing Global Adult Stem Cells Market Report:

New approaches and latest development trend that describe the structure of the market Advanced market breakdown structure Historical data and future market scope In-depth market analysis based on statistics, growth stimulators, and market developments Statistical data representation through figurative, numerical, and theoretical elaboration Report provides insight of the business and sales activities Key competitive players and regional distribution will help find prospective market analytics Report will strengthen the investors decision-making processes

Continue reading here:
Global Adult Stem Cells Market Revenue To Witness Humongous Elevation By 2026 Market Research Store Jumbo News - Jumbo News

Reactivation of the pluripotency program precedes formation of the cranial neural crest – Science Magazine

By Embryonic Stem Cells

Reactivating neural crest pluripotency

Cranial neural crest cells (CNCCs) are a transient cell group with an extraordinary differentiation potential that extends beyond its ectodermal lineage to form the majority of facial mesenchyme. Zalc et al. identified a neuroepithelial precursor population that transiently reactivates pluripotency factors to generate CNCCs. The pluripotency factor Oct4 is required for the expansion of CNCC developmental potential to form facial mesenchyme. Analysis of the chromatin landscape of Oct4+ CNCC precursors showed that these cells resemble those of epiblast stem cells, with additional features suggestive of future priming for neural crest programs. Thus, to expand their cellular potency, CNCC precursors undergo a natural in vivo reprogramming event.

Science, this issue p. eabb4776

Cell differentiation is classically described as a unidirectional process that progresses through a series of lineage restriction events, with cellular potential being increasingly reduced as the embryo develops, a concept famously illustrated by Conrad Waddington in his epigenetic landscape. However, the vertebrate-specific transient cell population called cranial neural crest cells (CNCCs) challenges this paradigm. Although they originate in the ectoderm and are capable of differentiating into cell types typical of this germ layer, CNCCs can also give rise to mesenchymal cell types canonically associated with the mesoderm lineage, such as bone, cartilage, and smooth muscle. How CNCCs expand their differentiation potential beyond their germ layer of origin remains unresolved.

We hypothesized that unbiased analysis of transcriptional heterogeneity during the early stages of mammalian CNCC development may identify a precursor population and provide clues as to how these specialized cells gain their extraordinary differentiation potential. To test this, we combined single-cell RNA-sequencing analysis of murine CNCCs from staged mouse embryos with follow-up lineage-tracing, loss-of-function, and epigenomic-profiling experiments.

We found that premigratory CNCCs are heterogeneous and carry positional information reflective of their origin in the neuroepithelium, but this early positional information is subsequently erased, with delaminating CNCCs showing a relatively uniform transcriptional signature that later rediversifies as CNCCs undergo first commitment events. We identify an early precursor population that expresses canonical pluripotency transcription factors and gives rise to CNCCs and craniofacial structures. Rather than being maintained from the epiblast, pluripotency factor Oct4 is transiently reactivated in the prospective CNCCs after head-fold formation, and its expression shifts from the most anterior to the more posterior part of the cranial domain as development progresses. Oct4 is not required for the induction of CNCCs in the neuroepithelium, but instead is important for the specification and survival of facial mesenchyme, thus directly linking this pluripotency factor with the expansion of CNCC cellular potential. Open chromatin landscapes of Oct4+ CNCC precursors are consistent with their neuroepithelial origin while also broadly resembling those of pluripotent epiblast stem cells. In addition, we saw priming of distal regulatory regions at a subset of loci associated with future neural crest migration and mesenchyme formation.

Our results show that premigratory CNCCs first form as a heterogeneous population that rapidly changes its transcriptional identity during delamination, resulting in the formation of a transcriptionally (and likely also functionally) equivalent cell group capable of adapting to future locations during and after migration. Such functional equivalency and plasticity of CNCCs is consistent with previous embryological studies. Furthermore, the demonstration that CNCC precursors transiently reactivate pluripotency factors suggests that these cells undergo a natural in vivo reprogramming event that allows them to climb uphill on Waddingtons epigenetic landscape. Indeed, our results show that at least one of the pluripotency factors, Oct4, is required for the expansion of CNCC developmental potential to include formation of facial mesenchyme. Whether this mechanism is specific to CNCCs and if such expansion of cellular plasticity could be harnessed for regenerative medicine purposes remain interesting questions for future investigations.

(A) Single-cell RNA (scRNA) sequencing of genetically labeled murine CNCCs over 14 hours of development revealed rapid transcriptional changes and identified a precursor population expressing pluripotency factors. (B) Uphill on Waddingtons epigenetic landscape, reactivation of Oct4 endows CNCC precursors with the ability to form derivatives typical of mesoderm, such as mesenchyme.

During development, cells progress from a pluripotent state to a more restricted fate within a particular germ layer. However, cranial neural crest cells (CNCCs), a transient cell population that generates most of the craniofacial skeleton, have much broader differentiation potential than their ectodermal lineage of origin. Here, we identify a neuroepithelial precursor population characterized by expression of canonical pluripotency transcription factors that gives rise to CNCCs and is essential for craniofacial development. Pluripotency factor Oct4 is transiently reactivated in CNCCs and is required for the subsequent formation of ectomesenchyme. Furthermore, open chromatin landscapes of Oct4+ CNCC precursors resemble those of epiblast stem cells, with additional features suggestive of priming for mesenchymal programs. We propose that CNCCs expand their developmental potential through a transient reacquisition of molecular signatures of pluripotency.

See the rest here:
Reactivation of the pluripotency program precedes formation of the cranial neural crest - Science Magazine

Should We Double The Age When Science Can Experiment On Babies? – 550 KTSA

By Embryonic Stem Cells

Back when embryonic-stem-cell and other types of experimentation on early embryos commenced, the scientists promised they would always limit their activities to embryos in Petri dishes to the maximum of 14 days in development. Just a collection of undifferentiated cells, they sophistically maintained. Well stop when the nervous system begins to develop. It was all a ruse. The 14 day rule, as it came to be known, only prevented that which could not be done. You see, the state of the science was such that embryos could not be maintained for longer. But it assuaged the peasants.

Besides, the scientists knew that the boundary wasnt intended to be permanent. It was just a way station until embryos could be maintained outside a womans body for more than two weeks. That time is now arriving, and so, of course, the push is now on to expand the limit to 28 days.

To talk about this push to disect babies, Lars spoke with Wesley Smith, an author and a senior fellow at the Discovery Institutes Center on Human Exceptionalism.

To read Wesleys full article click HERE

Listen to the interview below:

The post Should We Double The Age When Science Can Experiment On Babies? appeared first on The Lars Larson Show.

See more here:
Should We Double The Age When Science Can Experiment On Babies? - 550 KTSA

Stem cells efficacy confirmed in treating ototoxic hearing loss – Korea Biomedical Review

By Stem Cell Treatment

() () URL()

Researchers at the Catholic University of Korea St. Marys Hospital have recently proved the efficacy of bone marrow-derived stem cells to treat ototoxicity hearing loss, the hospital said Thursday.

The team, led by Professor Park Kyoung-ho of the Department of Otolaryngology, conducted an experiment on animal models with ototoxic sensorineural hearing, or sudden hearing loss.

They utilized Catholic MASTER cells, bone marrow stem cells developed by the Catholic Institute of Cell Therapy, to compare the stem cell injection group with the controlled group.

The result showed that animals started to recover their hearing after three weeks. Five weeks later, they recovered normal hearing at 8000Hz, 16000Hz and 32000Hz frequency.

Ototoxic hearing loss is caused when a person ingests chemicals or certain medications that adversely affect the inner ear functions. Major symptoms related to the illness are dizziness, false hearing, and hearing loss, which permanently defects hearing functions. Elders with such symptoms should have medical consultations as they are a high-risk group, the hospital said.

We have proved the efficacy of our bone marrow stem cells in recovering hearing, said Professor Park, who doubles as the director of the Stem Cell Institute. Through the results, we expect to provide new treatment opportunities for patients with hearing loss.

The test results were published in the Korean Journal of Otorhinolaryngology-Head and Neck Surgery.

See the article here:
Stem cells efficacy confirmed in treating ototoxic hearing loss - Korea Biomedical Review

Global Retinitis Pigmentosa (Retinitis) Market demand with COVID-19 recovery analysis 2021 better delivery process to boost market growth by 2026 KSU…

By Gene Therapy Clinics

Retinitis-Pigmentosa-(Retinitis)-MarketLatest research on Global Retinitis Pigmentosa (Retinitis) Market report covers forecast and analysis on a worldwide, regional and country level. The study provides historical information of 2016-2021 together with a forecast from 2021 to 2026 supported by both volume and revenue (USD million). The entire study covers the key drivers and restraints for the Retinitis Pigmentosa (Retinitis) market. this report included a special section on the Impact of COVID19. Also, Retinitis Pigmentosa (Retinitis) Market (By major Key Players, By Types, By Applications, and Leading Regions) Segments outlook, Business assessment, Competition scenario and Trends .The report also gives 360-degree overview of the competitive landscape of the industries.Moreover, it offers highly accurate estimations on the CAGR, market share, and market size of key regions and countries. Players can use this study to explore untapped Retinitis Pigmentosa (Retinitis) markets to extend their reach and create sales opportunities.

Some of the key manufacturers operating in this market include: Sanofi, Amgen, Amarantus Bioscience Holdings, Acucela, Applied Genetic Technologies Corp, Asklepios BioPharmaceutical, Astellas Pharma, Caladrius Biosciences, Dompe Farmaceutici SpA, Dormant Projects, GenSight Biologics SA, Grupo Ferrer Internacional SA, ID Pharma, InFlectis BioScience, Ionis Pharmaceuticals, Mimetogen Pharmaceuticals, Ms Science Corp, Nanovector srl, Novartis AG, Novelion Therapeutics, ProQR Therapeutics, ReNeuron Group Plc, SanBio, Shire (Takeda Pharmaceutical), Spark Therapeutics and More

Download Free PDF Sample Copy of the Report(with covid 19 Impact Analysis): https://www.globmarketreports.com/request-sample/61185

Our Research Analyst implemented a Free PDF Sample Report copy as per your Research Requirement, also including impact analysisofCOVID-19 on Retinitis Pigmentosa (Retinitis) Market Size

Retinitis Pigmentosa (Retinitis) market competitive landscape offers data information and details by companies. Its provides a complete analysis and precise statistics on revenue by the major players participants for the period 2021-2026. The report also illustrates minute details in the Retinitis Pigmentosa (Retinitis) market governing micro and macroeconomic factors that seem to have a dominant and long-term impact, directing the course of popular trends in the global Retinitis Pigmentosa (Retinitis) market.

Based on the type of product, the global Retinitis Pigmentosa (Retinitis) market segmented into: General Treatment Traditional Chinese Medicine Gene Therapy The Surgical Treatment Others

Based on the end-use, the global Retinitis Pigmentosa (Retinitis) market classified into: Hospitals Eye Clinics Others

Regions Covered in the Global Retinitis Pigmentosa (Retinitis) Market:

1. South America Retinitis Pigmentosa (Retinitis) Market Covers Colombia, Brazil, and Argentina. 2. North America Retinitis Pigmentosa (Retinitis) Market Covers Canada, United States, and Mexico. 3. Europe Retinitis Pigmentosa (Retinitis) Market Covers UK, France, Italy, Germany, and Russia. 4. The Middle East and Africa Retinitis Pigmentosa (Retinitis) Market Covers UAE, Saudi Arabia, Egypt, Nigeria, and South Africa. 5. Asia Pacific Retinitis Pigmentosa (Retinitis) Market Covers Korea, Japan, China, Southeast Asia, and India.

Years Considered to Estimate the Market Size: History Year: 2015-2021 Base Year: 2021 Estimated Year: 2021 Forecast Year: 2021-2026

Get Chance of up to 50% Extra Discount@: https://www.globmarketreports.com/request-discount/61185

Reasons to buy:

Some Major TOC Points:

For More Information with including full TOC: https://www.globmarketreports.com/industry-reports/61185/Retinitis-Pigmentosa-(Retinitis)-market

Key highlights of the Retinitis Pigmentosa (Retinitis) Market report: Growth rate Renumeration prediction Consumption graph Market concentration ratio Secondary industry competitors Competitive structure Major restraints Market drivers Regional bifurcation Competitive hierarchy Current market tendencies Market concentration analysis

Customization of the Report: Glob Market Reports provides customization of reports as per your need. This report can be personalized to meet your requirements. Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.

Get Customization of the Report@: https://www.globmarketreports.com/request-customization/61185

Contact Us: Glob Market Reports 17224 S. Figueroa Street, Gardena, California (CA) 90248,United States Call:+1 915 229 3004(U.S) +44 7452 242832(U.K) Website: http://www.globmarketreports.com

View original post here:
Global Retinitis Pigmentosa (Retinitis) Market demand with COVID-19 recovery analysis 2021 better delivery process to boost market growth by 2026 KSU...

ASCO Names Molecular Profiling in GI Cancers as Advance of the Year – OncLive

By Gene Therapy Clinics

Molecular profiling has paved the way for several advances in the treatment of patients with gastrointestinal (GI) malignancies, by identifying critical markers and gene signatures that allow for the delivery of options that are personalized to each tumor. To this end, ASCO has chosen molecular profiling driving progress in GI cancers as its Advance of the Year.1

The organization made the announcement as part of its Clinical Cancer Advances 2021: ASCOs Annual Report on the Progress Against Cancer. The annual update shines a light on important clinical research milestones and policy developments that have been made over the past year; the report also spotlights areas of opportunity to address unmet needs with future efforts.

Molecular profiling tools such as next-generation sequencing give us the ability to identify specific molecular and genomic-targeted treatments that are likely to benefit an individual patient, Howard A. Skip Burris, III, MD, FACP, FASCO, ASCO board chairman, stated in a press release.2 Personalized medicine is becoming a reality.

Although treatments such as surgery, radiotherapy, and chemotherapy have served as the mainstay of treatment in patients with GI cancers, these approaches have limited efficacy and can negatively impact quality of life, according to the report. Although the development of more effective approaches has lagged, the advent of molecular profiling has helped to expand options for these patients; this has resulted in longer survival with minimal adverse effects.

The ability to identify genetic abnormalities, such as mutations, amplifications, or fusions, as well as epigenetic profile, protein expression, or other molecular features has allowed for patients to be matched with the appropriate targeted therapy for their specific tumor. In the past year, HER2-targeted agents have been shown to improve survival in patients with gastric cancer; this approach is showing similar potential in patients with HER2-positive colorectal cancer (CRC).

Several HER2-targeted agents are being examined in patients with GI cancers. For example, the safety and efficacy of the novel HER2-targeted antibodydrug conjugate (ADC) fam-trastuzumab deruxtecan-nxki (Enhertu) was evaluated in patients with HER2-positive gastric or gastroesophageal cancers who had progressed on trastuzumab (Herceptin) as part of the phase 2 DESTINY-Gastric01 trial (NCT03329690).3

Patients who received trastuzumab deruxtecan achieved an objective response rate (ORR) of 51.3% versus 14.3% in those who received chemotherapy. Patients on the trastuzumab deruxtecan arm also experienced an improvement in median overall survival (OS) compared with those on the chemotherapy arm, at 12.5 months versus 8.4 months, respectively (HR, 0.59; 95% CI, 0.39-0.88; P = .0097). The benefit achieved with the ADC led to the January 2021 approval of trastuzumab deruxtecan for use in adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma who had previously received a trastuzumab-based regimen.4

Additional data on the agent were presented during the 2020 ASCO Virtual Scientific Program. In thephase 2 DESTINY-CRC01 study (NCT03384940), trastuzumab deruxtecan was examined in 78 patients with HER2-expressing, metastatic CRC who had progressed on 2 or more prior regimens. Here, 1 patient experienced a complete response to treatment, while 23 experienced partial responses.5 In this population, the agent yielded an ORR of 45.3%.

Another advancement was the June 2020 FDA approval of first-line pembrolizumab (Keytruda) for patients with microsatellite instabilityhigh or mismatch repair deficient CRC.6 This regulatory decision on was based on the results from the phase 3 KEYNOTE-177 trial (NCT02563002), in which the PD-1 inhibitor was found to double the time to disease progression versus standard chemotherapy, at 16.5 months versus 8.2 months, respectively.7 Moreover, pembrolizumab resulted in a significant 40% reduction in the risk of disease progression or death versus chemotherapy (HR, 0.60; 95% CI, 0.45-0.80; P = .0004).

The report also examined health inequities in cancer care and clinical research. Although overall cancer-related mortality has decreased in the United States, underserved patient populations still experience lower survival; these populations include black patients, those residing in rural areas, and those with lower incomes and education levels.8,9

Disparities in cancer research is a complex, multifaceted issue requiring a multifactorial response that addresses (1) specific interrelated barriers precluding certain populations from trial participation, and (2) structural and systemic challenges that limit the cancer communitys pursuit of research that would benefit underserved populations, the authors of the report write.

Some obstacles to equitable cancer research can include structural barriers, such as a lack of access to clinics offering clinical trials, as well as transportation and health insurance; clinical barriers, such as eligibility criteria; patient attitudes regarding trials, which could stem from historical inequities and a lack of informed consent; and physician attitudes, such as not offering underserved patients the opportunity to enroll to relevant clinical trials.

The authors of the report suggest several strategies to potentially improve equity in clinical cancer research. To this end, ASCO and Friends of Cancer Research have been working together to finalize 4 new Guidance for Industry documents that would broaden eligibility criteria for clinical trials by lowering the minimum participation age and to include patients with brain metastases who have been treated and are stable. Additionally, expanded guidelines would include patients with human immunodeficiency virus and hepatitis B and C virus, and recommend less restrictive renal, cardiac, and hepatic function criteria.

Other efforts include umbrella and basket trial designs, broadening trial availability, improving patient education and navigation, developing new consent strategies, and providing more financial assistance plans.

Among the numerous developments listed in the report, authors underscored the importance of artificial intelligence (AI) technology, a complex field of medical research that has grown exponentially in recent years. Authors of the report noted that AI technology can potentially be used to integrate a wealth of data points into a clinically meaningful context.

Currently, several types of AI are being utilized in the field of oncology, including deep learning methods that are able to identify relationships within data to solve complex problems through the utilization of algorithms in an iterative process. This technology could help to advance diagnostic, therapeutic, and translational research in both cancer prevention and treatment.

Key areas of interest include the development of deep learning methodologies to help with diagnosing cancer based on biospecimen analysis; using AI to improve radiographic imaging, analysis, and reporting; and using these systems to integrate vast amounts of clinical data to assist in the clinical decision-making process and measure outcomes.

It will be critical to educate oncologist about the fundamentals, advantages, and potential pitfalls of AI and deep learning techniques to support effective application in real-world cancer care, according to the authors of the report.

The coronavirus disease 2019 (COVID-19) pandemic has provided a unique opportunity for investigators to reconsider how clinical cancer research can be conducted and to examine disparities that exist with regard to clinical trial participation. Within the first weeks of the pandemic, 60% of US research institutions froze screening and enrollment for clinical trial research.10

To address this, investigators and institutions, with help from the FDA and the National Comprehensive Cancer Network, took action. To avoid the shutdown of clinical trials, investigator and sponsors found ways to allow for some flexibility, while preserving the integrity of the research. Remote patient monitoring and drug administration were permitted, and guidance was created to allow for virtual consent using e-signatures and limited collection of research-only biospecimens. Moreover, patients were allowed to have their local healthcare providers perform blood draws and imaging scans for these efforts.

Although the pandemic spotlighted existing racial and socioeconomic disparities, it also underscored the ability of the oncology community to rapidly respond to significant, unexpected disruptions to care and research efforts.

This same ingenuity and flexibility can and should be applied to improving health equity for all individuals, so that right treatment truly is delivered to the right patient at the right time, everywhere, the authors of the report wrote.

Go here to see the original:
ASCO Names Molecular Profiling in GI Cancers as Advance of the Year - OncLive

Regenerative Medicine Market to be Valued at USD 6.49 Billion by 2027 | The Escalating Burden of Chronic Diseases and Genetic Aberrations will be the…

By Stell Cell Research

February 04, 2021 07:46 ET | Source: Emergen Research

Vancouver, British Columbia, Feb. 04, 2021 (GLOBE NEWSWIRE) -- The Global Regenerative Medicine Market is predicted to attain a market valuation of USD 6.49 billion by 2027, growing at a CAGR of 9.3% throughout the estimated period, according to a recent analysis by Emergen Research. Targeted therapy of specific disease indication and chronic illnesses are anticipated to alter the dynamics of the healthcare field. The escalating prevalence of chronic health conditions and increasing patient pool of geriatric populace coupled with neurodegenerative disorders, cancers, orthopedic, and other age-related conditions are further bolstering the industrys expansion.

The numerous applications and subsequent advancements in tissue engineering, gene therapy, nanotechnology, and stem cells research are foreseen to boost the scope of regenerative medicine. 3D printing is playing a pivotal role in stem cells research as it allows for the easy restoration of structural and functional properties.

North America is predicted to occupy a significant share of the market in the projected timeframe and the growth can be attributed to the increasing number of academic institutions and universities extensively exploring regenerative medicine approaches based on stem cells.

Claim Your FREE Sample Copy with Table of content@ https://www.emergenresearch.com/request-sample-form/9

Key Highlights from the Report:

Claim Your FREE Sample Copy with Table of content@ https://www.emergenresearch.com/request-sample-form/9

For the purpose of this report, Emergen Research has segregated the Global Regenerative Medicine Market on the basis of product, therapeutic category, application, and region:

Product Outlook (Volume, Million Tons; Revenue, USD Billion; 2017-2027)

Therapeutic Category Outlook (Volume, Million Tons; Revenue, USD Billion; 2017-2027)

Application Outlook (Volume, Million Tons; Revenue, USD Billion; 2017-2027)

Click to access the Report Study, Read key highlights of the Report and Look at Projected Trends: https://www.emergenresearch.com/industry-report/regenerative-medicine-market

Regional Outlook (Volume, Million Tons; Revenue, USD Billion; 2017-2027)

Take a Look at our Related Reports:

Topical Drug Delivery Market By Product Form (Semi-Solid, Solid Formulations, Transdermal Products, and Liquid Formulations), By Route (Dermal, Ophthalmic, Nasal, Others), By End-Use (Hospitals, Home Healthcare, Clinics, Diagnostic Centers, Burn Center), and By Regions

Medical Smart Textiles Market By Technology (Textile Sensors, Wearable Technology), By Application (Surgery, Bio-Monitoring, Therapy, and Wellness), By End-use (Hospitals and Clinics, Medical Academic and Research Center), and By Region

Operating Room Management Solutions Market By Solution Type (Data management and communication solutions, Operating room supply management solutions, Anesthesia information management solutions, Operating room scheduling solutions, Performance management solutions), By Mode of Deployment (Ob-premises, Cloud-based), By End-Use (Hospitals, Ambulatory surgical centers), and By Region

Patient Registry Software Market By Delivery, By Database, By Registry Type, By Function, By Software Type (Integrated, Standalone), By End-use (Government & Third-Party Administrators, Pharmaceutical Companies, Hospitals, Research Centers, Others), and By Region, Forecast to 2027

Ambulatory EHR Market By Deployment (Cloud-based, On-premises), By Practice Size (Solo Practices, Large Practices, Small-medium-sized Practices), By Application, By End-use (Independent Centers, Hospital-owned Ambulatory Centers, Others), and By Region, Forecasts to 2027

About Emergen Research

Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Emergen Research has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

Contact Us:

Eric Lee

Corporate Sales Specialist

Emergen Research | Web: http://www.emergenresearch.com

Direct Line: +1 (604) 757-9756

E-mail: sales@emergenresearch.com

Facebook | LinkedIn | Twitter | Blogs

Read Full Press Release: https://www.emergenresearch.com/press-release/global-regenerative-medicine-market

Read more here:
Regenerative Medicine Market to be Valued at USD 6.49 Billion by 2027 | The Escalating Burden of Chronic Diseases and Genetic Aberrations will be the...

Turn Biotechnologies Expands the Potential of its mRNA Platform by Licensing Unique Artificial Niche Technology – PRNewswire

By Stell Cell Research

MOUNTAIN VIEW, Calif., Feb. 3, 2021 /PRNewswire/ --Turn Biotechnologies, a company developing medicines for currently untreatable age-related conditions, announced that it has acquired the global rights for new artificial niche (AN) technology that can be used to restore muscle stem cells damaged by aging.

The company licensed its AN technology from Stanford University, where it was developed by a researcher who serves as an advisor to Turn. AN technology is used to create a microenvironment that maintains stem cells in a quiescent state to repair or replace specific types of damaged tissue. The stem cell niche provides structural and trophic support and the appropriate homeostasis to regulate stem cell function.

Turn will use the niche technology in combination with its mRNA-based epigenetic reprogramming of age (ERA) technology to restore specific cells' youthful functionality, to trigger the body's ability to fight age-related diseases.

"Our artificial niche technology expands the applicability of our ERA technology to a variety of diseases involving tissue that requires a microenvironment to maintain cell quiescence," said Anja Krammer, Turn CEO. "By enveloping our ERA technology in the protective matrix of an artificial niche, we can reactivate muscle stem cells, as well as stem cells in tissues where quiescence is necessary to maintain stem cell functions."

The combined use of Turn's AN and ERA technologies may be able to restore function in hematopoietic, liver, brain, certain mesenchymal stem cells across different tissues and within the hair follicle.

This is Turn's second licensing announcement since the start of the year. Earlier, the company revealed that it acquired the global rights for its ERA technology from Stanford University, where it was developed by three researchers who founded Turn. It is the first technology to maintain cellular identity while restoring specific cells' youthful functionality, to trigger the body's ability to fight age-related diseases.

As with ERA, the company announced that it has filed for patents to protect its AN technology in major-market nations on six continents.

"This is significant for our pipeline because the combination of AN with our ERA technology in murine models shows increased potency," said Jay Sarkar, Turn's chief technology officer and a company founder who helped to develop the ERA technology. "The studies show that aged muscle stem cells treated with this combination therapy fully regenerate age-related muscle dysfunctions."

Turn's technology uses messenger RNA to produce instructions that induce cells to treat or prevent disease. Use of mRNA, which led to the quick development of two COVID-19 vaccines, promises to revolutionize the development of therapeutics by making that development safer, faster, more efficient and extremely tunable to patient need.

Turn is currently completing pre-clinical research on tailored therapies targeting indications in dermatology, ophthalmology, osteo-arthritis and cartilage damage and musculature.

ABOUT TURN BIOTECHNOLOGIES

Turn is a pre-clinical-stage company focused on repairing tissue at the cellular level. Our proprietary mRNA technology combats the effects of aging in the epigenome, thus restoring optimal gene expression and enabling cells to function as vigorously as when they were younger. Our technology provides a platform from which to attack a variety of diseases related to age. The company has the financial backing of Methuselah Fund, which focuses its investments to extend the healthy human lifespan; Formic Ventures, which invests in biotech start-ups focused on human longevity; and Shanda Group, a private global investment firm. For more information, see http://www.turn.bio.

FOR MORE INFORMATION, CONTACT: Jim Martinez, rightstorygroup [emailprotected] or (312) 543-9026

SOURCE Turn Biotechnologies

Continued here:
Turn Biotechnologies Expands the Potential of its mRNA Platform by Licensing Unique Artificial Niche Technology - PRNewswire

Evotec and Medical Center Hamburg-Eppendorf Enter Partnership to Develop iPSC-Based Tissue Therapy for Heart Failure – Yahoo Finance UK

By Stell Cell Research

Bloomberg

(Bloomberg) -- Stocks extended their rally into a fourth day as traders parsed through a flurry of corporate results amid signs the U.S. labor market may be gradually improving. The dollar climbed.The S&P 500 headed toward a record, led by banks and tech shares, as the Russell 2000 Index jumped 1.8%. EBay Inc. and PayPal Holdings Inc. surged on upbeat forecasts, while Netflix Inc. gained on news its raising the price of its service in Japan. Meanwhile, GameStop Corp. plunged as day traders flocked to other stocks like drug developers, and Nordstrom Inc. slid after announcing a strategy to win back customers -- a sign that Wall Street may have expected a more comprehensive overhaul. A widely watched segment of the Treasury yield curve steepened to levels last seen in 2015.The bull market in U.S. stocks remains on solid footing as the rebound in activity and corporate profits alongside an accommodative Federal Reserve create a supportive environment for equities, according to UBS Group AG. A report Thursday showed jobless claims fell to the lowest since November, and the next major update on the economy comes on Friday -- with analysts forecasting the labor market added about 100,000 jobs in January after a 140,000 drop in December. Selected high-frequency data, such as weekly consumer-confidence readings, also point to some strengthening.We certainly seem to have shifted our focus back to fundamentals, said Arthur Hogan, chief market strategist at National Securities Corp. The virus news is getting incrementally better at the very same time that the earnings season and economic data seem to be showing some improvement. Markets are actually focusing on what were supposed to be focused on and less concerned about the machinations of getting fiscal policy out and whats going on in Reddit-land.The Reddit-fueled rumble in the U.S. stock market may have heightened fears of another burst of volatility, according to options data tracked by Bloomberg. Over the last two weeks, the Cboe Volatility Indexs futures curve has shifted markedly higher, showing a pronounced peak in April before a gradual decline. The move suggests investors expect more volatility in the short-term amid concerns about extended valuations, the pace of the vaccine rollout and the impact of retail-trading activity.These are some of the main moves in markets:StocksThe S&P 500 increased 0.8% as of 3:34 p.m. New York time.The Stoxx Europe 600 Index rose 0.6%.The MSCI Asia Pacific Index decreased 0.7%.CurrenciesThe Bloomberg Dollar Spot Index rose 0.4%.The euro dipped 0.6% to $1.1965.The Japanese yen depreciated 0.5% to 105.55 per dollar.BondsThe yield on 10-year Treasuries fell less than one basis point to 1.14%.Germanys 10-year yield climbed one basis point to -0.45%.Britains 10-year yield jumped seven basis points to 0.44%.CommoditiesWest Texas Intermediate crude rose 1% to $56.26 a barrel.Gold lost 2.1% to $1,794.80 an ounce.Silver fell 2% to $26.35 per ounce.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.2021 Bloomberg L.P.

Read this article:
Evotec and Medical Center Hamburg-Eppendorf Enter Partnership to Develop iPSC-Based Tissue Therapy for Heart Failure - Yahoo Finance UK

Biobanks Market | Prominent Factors Analysis that will Help in Reshaping the Market Growth – BioSpace

By Stell Cell Research

Biobanks are essentially repositories for storing biological substances derived from humans, which may include organs, bio-specimens, plasma, saliva, and blood. With a vast rise in the number of organ replacement surgeries globally and significant advancements made in the fields of transfusion and replacement technologies, the role of the biobanks market has become more concrete in the healthcare sector in recent years.

The global biobanks market has witnessed expansion at a significant pace in the recent years owing to the vast rise in prevalence of a number of chronic diseases and the increased demand for personal medicine. The massive rise in incidence rate of conditions such as diabetes, cancer, neurovascular diseases, cardiovascular diseases, and respiratory diseases has compelled government bodies to take stronger actions in terms of investments in biobanks and increasing awareness about them. The global market for biobanks works in coherence with these efforts by adding pace to the process of drug discovery and the treatment of chronic diseases that are caused by activities such as smoking, consumption of alcohol, obesity, and unhealthy lifestyles.

Get Brochure of the Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=2321

Heavy investment by a proactive government has boosted the North America biobanks market to the leading position in the global biobanks market, followed closely by Europe. Both regions are home to several bioscience companies and host a large number of drug discovery and research activities. Asia Pacific still remains the region with the most promising growth potential as the region shown high promise owing to an increase in investments from both government and non-government organizations, along with a large and increasingly affluent population base that is gaining awareness about the market.

Global Biobanks Market: Overview

The global biobanks market owes its conception to the rising need for replacement organs and the steady advancement in the replacement and transfusion technologies regarding a number of bodily substances. Though the technology and need to store organs and other bio-entities had been available for a long time, the global biobanks market took on a more important role in the healthcare sector following the increasing research in genomics. In the new millennium, the development of the personalized medicine field has been the vital driver for the global biobanks market. The likely advancement of the latter, thanks to helpful government regulations, is likely to make the crucial difference for the global biobanks market in the near future.

The steady technological advancement in the healthcare sector in the last few decades has now led to a scenario where the full potential of biobanks can be harnessed. As a result, the global biobanks market is projected to exhibit steady growth over the coming years.

Global Biobanks Market: Key Trends

The rising interest in personalized medicine is the prime driver for the global biobanks market. Personalized medicine has only become a viable branch of modern medicine after steady research in genomics and the way various patients react to various medicines. The biobanks market has thus come into the spotlight thanks to their role as a steady supplier of human biomaterials for research as well as direct application. The increasing research in genomics following the findings of the Human Genome Project is thus likely to remain a key driver for the global biobanks market in the coming years.

Buy this Premium Report @ https://www.tmrresearch.com/checkout?rep_id=2321&ltype=S

The utilization of biobanks in stem cell research has been hampered in several regions by ethical concerns regarding the origin of stem cells. Nevertheless, the potential of stem cells in the healthcare sector is immense, and is likely to have a decisive impact on the trajectory of the global biobanks market in the coming years. Many countries have, in recent years, adopted a supportive stance towards stem cell research, aiding the growth of the biobanks market. Continued government support is thus likely to remain vital for the global biobanks market in the coming years.

Global Biobanks Market: Market Potential

The leading role of the U.S. in the global biobanks market is unlikely to change in the coming years. The easy availability of government-supported healthcare infrastructure and the presence of several industry giants in the region has driven the biobanks market in the U.S.

Northwell Health, the largest healthcare provider in New York State, earlier in 2017 initiated a new biobank aimed at creating precision therapies against various types of cancer. Launched in collaboration with Indivumed, the biobank will provide catalogued biomaterials for research into lung, colorectal, breast, and pancreatic cancer. This would enable targeted, gene-specific studies of a variety of cancer samples, leading to a more comprehensive understanding of cancer. Such well-funded collaboration efforts are crucial for the developing biobanks market.

Global Biobanks Market: Geographical Dynamics

Led by the fertile healthcare research scenario in the U.S., North America is likely to retain a dominant share in the global biobanks market in the coming years. Steady support from institutes such as the NIH is likely to be vital for the North America biobanks market.

Emerging Asia Pacific economies such as India and China could emerge with a significant share in the global biobanks market in the coming years. The healthcare sector in both countries has received steady public or private funding in the last few years. India is also a global leader in medical tourism and is likely to receive an increasing number of patients in the coming years, leading to promising prospects for the global biobanks market in the region.

Global Biobanks Market: Competitive Dynamics

Due to the dynamic nature of the global biobanks market, with advancements in diagnostic fields often determining the direction of the market, the market is heavily fragmented. It is likely to retain a significant degree of fragmentation in the coming years thanks to the diversity in the application segments of the biobanks market. The leading players in the global biobanks market include BioCision, Tecan Group, VWR, Beckman Coulter Inc., and Thermo Fisher Scientific.

Get Table of Content of the Report @ https://www.tmrresearch.com/sample/sample?flag=T&rep_id=2321

About TMR Research

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Contact:

Rohit Bhisey

TMR Research,

3739 Balboa St # 1097,

San Francisco, CA 94121

United States

Tel: +1-415-520-1050

Visit Site: https://www.tmrresearch.com/

See the original post here:
Biobanks Market | Prominent Factors Analysis that will Help in Reshaping the Market Growth - BioSpace

→←